Third consensus on medical treatment of metastatic breast cancer (2009)
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., ...
Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. Design: To provide timely and...
Révillion, F., Lhotellier, V., Hornez, L., Bonneterre, J.
Background: The aim of this study is to provide an expression profile of ErbB/HER ligands in breast cancer. We analysed the relationships with their receptors, the bio-pathological features and...
Second consensus on medical treatment of metastatic breast cancer (2007)
BESLIJA, S, BONNETERRE, J, BURSTEIN, H, Cocquyt, Veronique, GNANT, M, GOODWIN, P, ...
Second consensus on medical treatment of metastatic breast cancer (2007)
Beslija, S, Bonneterre, J, Burstein, H, Cocquyt, V, Gnant, M, Goodwin, P, ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Roché, H., Kerbrat, P., Bonneterre, J., Fargeot, P., Fumoleau, P., Monnier, A., ...
Background: The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to...
Second consensus on medical treatment of metastatic breast cancer (2006)
Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Namer, M., Fargeot, P., Roché, H., Campone, M., Kerbrat, P., Romestaing, P., ...
Background: The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1–3),...
Fumoleau, P., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., ...
Background: The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E−)...
Roché, H., Kerbrat, P., Bonneterre, J., Fargeot, P., Fumoleau, P., Monnier, A., ...
Background: The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to...
Second consensus on medical treatment of metastatic breast cancer (2006)
Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., ...
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Piccart, MJ, Sledge, G, Carmichael, J, Luck, HJ, Mackey, JR, Nabholtz, JM, ...
Inst Jules Bordet, B-1000 Brussels, Belgium. Limburgs Univ Ctr, Diepenbeek, Belgium. IDDI, Brussels, Belgium.
Piccart, MJ, Sledge, G, Carmichael, J, Luck, HJ, Mackey, JR, Nabholtz, JM, ...
Limburgs Univ Centrum, Diepenbeek, Belgium. Inst Jules Bordet, B-1000 Brussels, Belgium. IDDI, Brussels, Belgium.
Piccart, MJ, BURZYKOWSKI, Tomasz, Sledge, G, Luck, HJ, Mackey, JR, Nabholtz, JM, ...
Inst Jules Bordet, B-1000 Brussels, Belgium. Limburgs Univ Ctr, Diepenbeek, Belgium. IDDI, Brussels, Belgium.
Piccart, MJ, Sledge, G, Carmichael, J, Luck, HJ, Mackey, JR, Nabholtz, JM, ...
Limburgs Univ Centrum, Diepenbeek, Belgium. Inst Jules Bordet, B-1000 Brussels, Belgium. IDDI, Brussels, Belgium.
ABE, O, ABE, R, ENOMOTO, K, KIKUCHI, K, KOYAMA, H, MASUDA, H, ...
ABE, O, ABE, R, ENOMOTO, K, KIKUCHI, K, KOYAMA, H, MASUDA, H, ...
Vanhuyse, M., Fournier, C., Bonneterre, J.
Background:: The aim of this study was to evaluate the influence of early chemotherapy-induced amenorrhea (CIA) on disease-free survival and overall survival in premenopausal patients with...
Campone, M., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., ...
Background: The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients. Patients and methods:...
Bonneterre, J., Bercez, C., Lenne, X., Dervaux, B.
Background: The aim of the study was to assess the incremental cost-effectiveness ratio (ICER) of the FEC 100 compared with the FEC 50 in the FASG05 trial. Materials and methods: A cost-effectiveness...
Arriagada, R., Lê, M. G., Spielmann, M., Mauriac, L., Bonneterre, J., Namer, M., ...
Purpose: The aim of this multicenter trial was to evaluate the role of ovarian suppression in patients with early breast cancer previously treated with local surgery and adjuvant chemotherapy....
Bonneterre, J., Bercez, C., Lenne, X., Dervaux, B.
Background: The aim of the study was to assess the incremental cost-effectiveness ratio (ICER) of the FEC 100 compared with the FEC 50 in the FASG05 trial. Materials and methods: A cost-effectiveness...
Vanhuyse, M., Fournier, C., Bonneterre, J.
Background: The aim of this study was to evaluate the influence of early chemotherapy-induced amenorrhea (CIA) on disease-free survival and overall survival in premenopausal patients with...
Campone, M., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., ...
Background: The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients. Patients and methods:...
Fumoleau, P., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., ...
Background: The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-)...
Consensus on medical treatment of metastatic breast cancer CECOG (2003)
BESLIJA, S, BONNETERRE, J, BURSTEIN, M, GNANT, P, GOODWIN, P, HEINEMAN, V, ...
Skovsgaard, T., Davidson, N. G. P., Piccart, M. J., Richel, D. J., Bonneterre, J., Cirkel, D.T., ...
background Eniluracil is an effective inactivator of dihydro-pyrimidine dehydrogenase, the initial and rate limiting enzyme in the catabolism of fluorouracil The current study was done to determine...
Bonneterre, J., Chevalier, B., Focan, C., Mauriac, L., Piccart, M.
Background: A phase I dose-escalation study of a new formulation of oral vinorelbine was conducted to determine the maximum tolerated dose (MTD) of a once weekly regimen and preliminary...
Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer (1994)
Degardin, M., Bonneterre, J., Hecquet, B., Adeins, A., Horner, D., ...
Background: Vinorelbine (Navelbine), a new vinca alkaloid, is an effective drug in breast cancer. Our study was undertaken to assess the efficacy and tolerance of Navelbine in refractory advanced...
Jammes, H., Peyrat, J. P., Ban, E., Vilain, M. O., Haour, F., Djiane, J., ...
To assess the precise role of IGF1 in benign and malignant breast diseases, we analysed the tissular localisation, characterised, and quantified specific insulin-like growth factor 1 (IGF1) binding...
Analysis of p16 gene deletion and point mutation in breast carcinoma.
Quesnel, B., Fenaux, P., Philippe, N., Fournier, J., Bonneterre, J., Preudhomme, C., ...
We looked for p16 gene deletion by Southern analysis and p16 gene point mutation by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing of DNA from fresh tumour samples of...
Smith, I., Jones, A., Spielmann, M., Namer, M., Green, M. D., Bonneterre, J., ...
ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer...
Peyrat, J. P., Révillion, F., Bonneterre, J.
Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in...
Kerbrat, P, Roché, H, Bonneterre, J, Veyret, C, Lortholary, A, Monnier, A, ...
The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m−2, epirubicin 100 mg m−2 and cyclophosphamide 500 mg m−2, six cycles every 21...
Bonneterre, J, Roché, H, Monnier, A, Guastalla, J P, Namer, M, Fargeot, P, ...
This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative...